32 THE BIOWORLD AND MEDICAL DEVICE DAILY OBESITY REPORT
Obesity Drugs: An Underweight Market Seeks Big Opportunites from a Growing Problem Obesity is a worldwide problem most obviously seen in developed countries. The Centers for Disease Control and Prevention estimates that more than a third of Americans – about 72 million people – are obese, and another third are overweight. If current trends continue, 43 percent of U.S. adults will be obese and obesity spending will quadruple to $344 billion by 2018, according to a study released in late 2009. On the other hand, if obesity rates hold steady, the U.S. would save nearly $200 billion in health care costs – or about $820 per adult. Based on research by Emory University, health care economist Ken Thorpe, executive director of the Partnership to Fight Chronic Disease, the report is the first to estimate obesity prevalence and costs at the state and national level 10 years from now. The report was commissioned by UnitedHealth Foundation, Partnership for Prevention and American Public Health Association in conjunction with their annual America’s Health Rankings report. “At a time when Congress is looking for savings in health care, this data confirms what we already knew: Obesity is where the money is,” Thorpe said. “Because obesity is related to the onset of so many other illnesses, stopping the growth of obesity in the U.S. is vital not only to our health – but also to the solvency of our health care system.” The report projects that obesity will comprise 50 percent of the adult population in six states, with an associated increase in health spending linked to obesity of more than $1,600 per person in each of these “worst” states: Kentucky, Maryland, Mississippi, Ohio, Oklahoma and South Dakota. Oklahoma is expected to have the highest obesity rate in the country by 2018. The report projects that the state’s obesity rate will be 56.1 percent by then, and that obesity-attributable health care spending will be $1,906 per adult. If obesity levels remain steady, however, it would provide a potential savings of $1,200 per adult or a savings of more than $3.2 billion for the state. According to the report, the obesity rate will stay below 35 percent in only four states and the District of Columbia. Nevertheless, the data shows that obesity-attributable health spending will climb to more than $800 per person by 2018 in each of these “best” states: Colorado, Connecticut, Massachusetts, Virginia and the District of Columbia. Colorado is estimated to have the lowest obesity rate by 2018 – 29.8 percent. Obesityattributable health spending in Colorado is expected to be $864 per adult. Body Mass Index of U.S. Population BMI Description U.S. Population 20-25 normal 25-29.9 overweight 30-39.9 obese 20 million 40-50 morbidly obese 5-10 million Over 50 superobese up to 5 million Source: Biomedical Business & Technology. BIOTECH DRUGS FOR OBESITY According to the report, Thorpe and colleagues from Emory developed an economic model to estimate the growth of health care costs over time that are attributable to changes in obesity rates. They used nationally representative data on adults to estimate the effect of the increasing prevalence Obesity Rankings by State Obesity Prevalence, Top Five Mississippi 32.0% Alabama 30.3% Tennessee 30.1% Louisiana 29.8% West Virginia 29.5% Bottom Five Hawaii 21.4% Rhode Island 21.4% Massachusetts 21.3% Vermont 21.3% Connecticut 21.2% Colorado 18.7% Source: Centers for Disease Control and Prevention. Aggregate <strong>Medical</strong> Spending Attributable to Overweight and Obesity by Insurance Status and Data Source, 1996–1998 (US$ billions) Insurance Overweight and Obesity Obesity Category MEPS (1998) NHA (1998) MEPS (1998) NHA (1998) Out-of-pocket $7.1 $12.8 $3.8 $6.9 Private $19.8 $28.1 $9.5 $16.1 Medicaid $3.7 $14.1 $2.7 $10.7 Medicare $20.9 $23.5 $10.8 $13.8 Total $51.5 $78.5 $26.8 $47.5 Source: Centers for Disease Control and Prevention. THE BIOWORLD AND MEDICAL DEVICE DAILY OBESITY REPORT 33
- Page 1 and 2: BIOWORLD ® & MEDICAL DEVICE DAILY
- Page 3 and 4: ABOUT BIOWORLD ® AND MEDICAL DEVIC
- Page 5 and 6: TABLE OF CONTENTS 13 An Abstract An
- Page 7 and 8: 62 Merck - taranabant 62 Neurogen -
- Page 9 and 10: 97 Movea 97 Novartis Medical Nutrit
- Page 11 and 12: 66 Balance of Drug/Device Sales in
- Page 13 and 14: An Abstract Analysis: Obesity Treat
- Page 15 and 16: More people are exercising, dieting
- Page 17 and 18: least desired, but most beneficial
- Page 19 and 20: In July 2004, the U.S. Department o
- Page 21 and 22: Health Consequences of Obesity Rese
- Page 23 and 24: School lunch programs Work demands
- Page 25 and 26: Global Hunger Statistics, cont. % c
- Page 27 and 28: uitous threat to good health, while
- Page 29 and 30: LeBron James, the superstar basketb
- Page 31: not inspiring optimism that they ar
- Page 35 and 36: of obesity on total direct health c
- Page 37 and 38: with some more promising data on ea
- Page 39 and 40: pharma to wait even longer. Cutler
- Page 41 and 42: increase energy usage, while topira
- Page 43 and 44: pay Deerfield a 2.25 percent transa
- Page 45 and 46: ic components - as low as one-sixte
- Page 47 and 48: FDA’s first goal, both doses hit
- Page 49 and 50: percent of Contrave patients vs. 42
- Page 51 and 52: Japanese market as well as Takeda.
- Page 53 and 54: Wall Street is watching for news of
- Page 55 and 56: ROCK2 and “has demonstrated signi
- Page 57 and 58: “stress” hormone, which, in exc
- Page 59 and 60: potential €171.5 million (US$230.
- Page 61 and 62: Znomics In April 2008, Znomics Inc.
- Page 63 and 64: Pfizer - CP-945,598 The obesity spa
- Page 65 and 66: Unfortunately, It’s a Growth Mark
- Page 67 and 68: tinal hormones to travel around the
- Page 69 and 70: performed nationwide. The study fou
- Page 71 and 72: Pouch Reduction,” Dean Mikami, of
- Page 73 and 74: EndoGastric Solutions - StomaphyX R
- Page 75 and 76: owel (as does gastric bypass surger
- Page 77 and 78: mental health and social functionin
- Page 79 and 80: for Type II diabetes. The company s
- Page 81 and 82: stomach via the mouth. A retraction
- Page 83 and 84:
ticularly serious health issues in
- Page 85 and 86:
that happened, EnteroMedics reduced
- Page 87 and 88:
corporate needs. The loan required
- Page 89 and 90:
patients a feeling of satiety. Afte
- Page 91 and 92:
Lansing Brown Investments and the C
- Page 93 and 94:
Companies with Interventional Thera
- Page 95 and 96:
Seahorse Bioscience Seahorse Biosci
- Page 97 and 98:
lent to those seen at high altitude
- Page 99 and 100:
Fat-Fighting Enzyme Can Play Havoc
- Page 101 and 102:
In the experiments reported in Cell
- Page 103 and 104:
acutely up-regulated by a high-fat
- Page 105 and 106:
the simultaneous occurrence of high
- Page 107 and 108:
eases such as Type I diabetes and C
- Page 109 and 110:
Personal Health Expenditures, by So
- Page 111 and 112:
Strength of Evidence on Lifestyle F
- Page 113 and 114:
CDC’s Recommended Community Strat
- Page 115 and 116:
Is Obesity an Epidemic in the U.S.?
- Page 117 and 118:
Health Care Costs of Obesity Obesit
- Page 119 and 120:
Obesity’s Impact on Health, cont.
- Page 121 and 122:
Number of Undernourished People in
- Page 123 and 124:
Obesity Deals and Data, cont. Modif
- Page 125 and 126:
1000 Genomes Project, 106-107 11BHS
- Page 127 and 128:
I Iceland, 25 ImpediMed, 94 Implant
- Page 129 and 130:
topiramate, 35, 37-42, 44-48 Toucan